Compared with PARP inhibitor or Cisplatin, SOSTDC1 knockdown did not impact cell sensibility to Docetaxel (DTX), which stops the growth of cancer cells by interfering with microtubules and blocking cell division (Figure S7B, Supporting Information). This evidence concerns the gene PARP1 and cancer.